GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The primary objective for this trial is to determine the effect of GB002 (seralutinib) on
improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH
who are Functional Class (FC) II and III. The secondary objective for this trial is to
determine the effect of GB002 (seralutinib) on improving exercise capacity in this
population.
Phase:
Phase 2
Details
Lead Sponsor:
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.